- 関
- neuropeptide Y receptor
WordNet
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
- the 14th letter of the Roman alphabet (同)n
PrepTutorEJDIC
- =sense organ / 受信装置
- nitrogenの化学記号
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/12/28 21:57:35」(JST)
[Wiki en表示]
| neuropeptide Y receptor Y1 |
| Identifiers |
| Symbol |
NPY1R |
| Alt. symbols |
NPYR |
| Entrez |
4886 |
| HUGO |
7956 |
| OMIM |
162641 |
| RefSeq |
NM_000909 |
| UniProt |
P25929 |
| Other data |
| Locus |
Chr. 4 q31.3-q32 |
| neuropeptide Y receptor Y2 |
| Identifiers |
| Symbol |
NPY2R |
| Entrez |
4887 |
| HUGO |
7957 |
| OMIM |
162642 |
| RefSeq |
NM_000910 |
| UniProt |
P49146 |
| Other data |
| Locus |
Chr. 4 q31 |
| pancreatic polypeptide receptor 1 |
| Identifiers |
| Symbol |
PPYR1 |
| Alt. symbols |
NPY4R, Y4, PP1 |
| Entrez |
5540 |
| HUGO |
9329 |
| OMIM |
601790 |
| RefSeq |
NM_005972 |
| UniProt |
P50391 |
| Other data |
| Locus |
Chr. 10 q11.2 |
| neuropeptide Y receptor Y5 |
| Identifiers |
| Symbol |
NPY5R |
| Entrez |
4889 |
| HUGO |
7958 |
| OMIM |
602001 |
| RefSeq |
NM_006174 |
| UniProt |
Q15761 |
| Other data |
| Locus |
Chr. 4 q31-q32 |
Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]
Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.
|
Contents
- 1 Types
- 2 Antagonists
- 3 References
- 4 External links
|
Types
There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[8] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[9][10][11]
- Y1 - NPY1R
- Y2 - NPY2R
- Y4 - PPYR1
- Y5 - NPY5R
Antagonists
- BIBP-3226
- Lu AA-33810
- BIIE-0246
- UR-AK49
References
- ^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. http://pharmrev.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9549761.
- ^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373.
- ^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800.
- ^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0002R.SGM.
- ^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213. http://www.bentham-direct.org/pages/content.php?PRN/2006/00000001/00000003/0008PRN.SGM.
- ^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0008R.SGM.
- ^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.
- ^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367.
- ^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.
- ^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0009R.SGM.
- ^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0010R.SGM.
External links
- "Neuropeptide Y Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. http://www.iuphar-db.org/GPCR/ChapterMenuForward?chapterID=1292.
- Neuropeptide+Y+Receptor at the US National Library of Medicine Medical Subject Headings (MeSH)
|
Cell surface receptor: G protein-coupled receptors
|
|
Class A:
Rhodopsin like |
|
|
| Class B: Secretin like |
|
Orphan
|
- GPR (56
- 64
- 97
- 98
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 123
- 124
- 125
- 126
- 128
- 133
- 143
- 144
- 155
- 157)
|
|
|
Other
|
- Brain-specific angiogenesis inhibitor (1
- 2
- 3)
- Cadherin (1
- 2
- 3)
- Calcitonin
- CALCRL
- CD97
- Corticotropin-releasing hormone (1
- 2)
- EMR (1
- 2
- 3)
- Glucagon (GR
- GIPR
- GLP1R
- GLP2R)
- Growth hormone releasing hormone
- PACAPR1
- GPR
- Latrophilin (1
- 2
- 3
- ELTD1)
- Methuselah-like proteins
- Parathyroid hormone (1
- 2)
- Secretin
- Vasoactive intestinal peptide (1
- 2)
|
|
|
Class C: Metabotropic
glutamate / pheromone |
|
Taste
|
- TAS1R (1
- 2
- 3)
- TAS2R (1
- 3
- 4
- 5
- 7
- 8
- 9
- 10
- 13
- 14
- 16
- 19
- 20
- 30
- 31
- 38
- 39
- 40
- 41
- 42
- 43
- 45
- 46
- 50
- 60)
|
|
|
Other
|
- Calcium-sensing receptor
- GABA B (1
- 2)
- Glutamate receptor (Metabotropic glutamate (1
- 2
- 3
- 4
- 5
- 6
- 7
- 8))
- GPRC6A
- GPR (156
- 158
- 179)
- RAIG (1
- 2
- 3
- 4)
|
|
|
Class F:
Frizzled / Smoothened |
|
Frizzled
|
- Frizzled (1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10)
|
|
|
Smoothened
|
|
|
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
Neuropeptide receptors
|
|
| G protein-coupled receptor |
|
Hormone receptors
|
|
Hypothalamic
|
CRH · FSH · LHRH · TRH · Somatostatin
|
|
|
Pituitary
|
Vasopressin (1A, 1B, 2) · Oxytocin · LHCG · TSH
|
|
|
Other
|
Atrial natriuretic factor (NPR3) · Calcitonin · Cholecystokinin (A, B) · VIP
|
|
|
|
Opioid receptors
|
Delta · Kappa · Mu · Nociceptin
|
|
|
Other neuropeptide receptors
|
Angiotensin · Bradykinin (B1, B2) / Tachykinin (TACR1) · Calcitonin gene-related peptide · Galanin · GPCR neuropeptide (B/W, FF, S, Y) · Neurotensin
|
|
|
| Type I cytokine receptor |
GH · Prolactin
|
|
| Enzyme-linked receptor |
Atrial natriuretic factor (NPR1, NPR2)
|
|
| Other |
Sigma (1, 2)
|
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
Neuropeptidergics
|
|
| Cholecystokinin |
|
CCKA
|
- Agonists: Cholecystokinin
- CCK-4
Antagonists: Asperlicin
- Proglumide
- Lorglumide
- Devazepide
- Dexloxiglumide
|
|
|
CCKB
|
- Agonists: Cholecystokinin
- CCK-4
- Gastrin
Antagonists: Proglumide
- CI-988
|
|
|
| CRH |
|
CRF1
|
- Agonists: Corticotropin releasing hormone
Antagonists: Antalarmin
- CP-154,526
- Pexacerfont
|
|
|
CRF2
|
- Agonists: Corticotropin releasing hormone
|
|
|
| Galanin |
|
GAL1
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
|
GAL2
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
|
GAL3
|
- Agonists: Galanin
- Galmic
- Galnon
|
|
|
| Ghrelin |
- Agonists: Ghrelin
- Capromorelin
- MK-677
- Sermorelin
- SM-130,686
- Tabimorelin
|
|
| GnRH |
- Agonists: Buserelin
- Deslorelin
- GnRH
- Goserelin
- Histrelin
- Leuprorelin
- Nafarelin
- Triptorelin
Antagonists: Abarelix
- Cetrorelix
- Degarelix
- Ganirelix
|
|
| MCH |
|
MCH1
|
- Agonists: Melanin concentrating hormone
Antagonists: ATC-0175
- GW-803,430
- NGD-4715
- SNAP-7941
- SNAP-94847
|
|
|
MCH2
|
- Agonists: Melanin concentrating hormone
|
|
|
| Melanocortin |
|
MC1
|
- Agonists: alpha-MSH
- Afamelanotide
- BMS-470,539
- Bremelanotide
- Melanotan II
Antagonists: Agouti signalling peptide
|
|
|
MC2
|
- Agonists: ACTH
- Cosyntropin
- Tetracosactide
|
|
|
MC3
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
|
|
|
MC4
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
- PF-00446687
- THIQ
Antagonists: Agouti-related peptide
|
|
|
MC5
|
- Agonists: alpha-MSH
- Melanotan II
|
|
|
| Neuropeptide S |
- Agonists: Neuropeptide S
Antagonists: SHA-68
|
|
| Neuropeptide Y |
|
Y1
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIBP-3226
|
|
|
Y2
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIIE-0246
|
|
|
Y4
|
- Agonists: Neuropeptide Y
- Pancreatic polypeptide
- Peptide YY
Antagonists: UR-AK49
|
|
|
Y5
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: Lu AA-33810
|
|
|
| Neurotensin |
|
NTS1
|
- Agonists: Neurotensin
- Neuromedin N
Antagonists: SR-48692
- SR-142,948
|
|
|
NTS2
|
- Agonists: Neurotensin
Antagonists: Levocabastine
- SR-142,948
|
|
|
| Orexin |
|
OX1
|
- Agonists: Orexin-A
Antagonists: Almorexant
- SB-334,867
- SB-408,124
- SB-649,868
- Suvorexant
|
|
|
OX2
|
- Agonists: Orexin-A
Antagonists: Almorexant
- SB-649,868
- Suvorexant
- TCS-OX2-29
|
|
|
| Oxytocin |
- Agonists: Carbetocin
- Demoxytocin
- Oxytocin
- WAY-267,464
Antagonists: Atosiban
- Epelsiban
- L-371,257
- L-368,899
- Retosiban
|
|
| Tachykinin |
|
NK1
|
- Agonists: Substance P
Antagonists: Aprepitant
- Befetupitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- FK-888
- Fosaprepitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium
- Orvepitant
- RP-67,580
- SDZ NKT 343
- Vestipitant
- Vofopitant
|
|
|
NK2
|
- Agonists: Neurokinin A
Antagonists: GR-159,897
- Ibodutant
- Saredutant
|
|
|
NK3
|
- Agonists: Neurokinin B
Antagonists: Osanetant
- Talnetant
|
|
|
| Vasopressin |
|
V1A
|
- Agonists: Desmopressin
- Felypressin
- Ornipressin
- Terlipressin
- Vasopressin
Antagonists: Conivaptan
- Demeclocycline
- Relcovaptan
|
|
|
V1B
|
- Agonists: Felypressin
- Ornipressin
- Terlipressin
- Vasopressin
Antagonists: Demeclocycline
- Nelivaptan
|
|
|
V2
|
- Agonists: Desmopressin
- Ornipressin
- Vasopressin
Antagonists: Conivaptan
- Demeclocycline
- Lixivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Comparative effects of intranasal neuropeptide Y and HS014 in preventing anxiety and depressive-like behavior elicited by single prolonged stress.
- Sabban EL1, Serova LI2, Alaluf LG2, Laukova M2, Peddu C2.
- Behavioural brain research.Behav Brain Res.2015 Dec 15;295:9-16. doi: 10.1016/j.bbr.2014.12.038. Epub 2014 Dec 24.
- Stress triggered neuropsychiatric disorders are a serious societal problem. Prophylactic treatment or early intervention has great potential in increasing resilience to traumatic stress and reducing its harmful impact. Previously, we demonstrated proof of concept that intranasal administration of ne
- PMID 25542511
- The role of pancreatic polypeptide in the regulation of energy homeostasis.
- Khandekar N1, Berning BA1, Sainsbury A2, Lin S3.
- Molecular and cellular endocrinology.Mol Cell Endocrinol.2015 Dec 15;418 Pt 1:33-41. doi: 10.1016/j.mce.2015.06.028. Epub 2015 Jun 27.
- Imbalances in normal regulation of food intake can cause obesity and related disorders. Inadequate therapies for such disorders necessitate better understanding of mechanisms that regulate energy homeostasis. Pancreatic polypeptide (PP), a robust anorexigenic hormone, effectively modulates food inta
- PMID 26123585
- Effect of Zinc on Appetite Regulatory Peptides in the Hypothalamus of Salmonella-Challenged Broiler Chickens.
- Hu X1, Sheikhahmadi A2, Li X1, Wang Y3, Jiao H1, Lin H1, Zhang B4, Song Z5.
- Biological trace element research.Biol Trace Elem Res.2015 Dec 5. [Epub ahead of print]
- The effects of dietary Zinc (Zn) supplementation on the gene expression of appetite regulatory peptides were investigated in Salmonella-infected broiler chickens. Broiler chickens (Arbor Acres, 1 day old) were allocated randomly into 24 pens of 10 birds. The chickens from 12 pens were fed with basa
- PMID 26637494
Japanese Journal
- Regulation of neuropeptide Y Y1 receptor expression by bone morphogenetic protein 2 in C2C12 myoblasts
- Kurebayashi Naoko,Sato Mari,Fujisawa Toshiaki,Fukushima Kazuaki,Tamura Masato
- Biochemical and Biophysical Research Communications 439(4), 506-510, 2013-10-04
- … The neuropeptide Y (NPY) system is known as one of the major neural signaling pathways. … NPY, produced by peripheral tissues including osteoblasts, is known to bind to the Y1 receptor. … Recently, osteoblast-specific Y1 receptor knockout mice were developed and were found to have a high bone mass phenotype, indicating a role for the NPY-Y1 receptor axis as a regulator of bone homeostasis. …
- NAID 120005324568
- Mechanisms of lifespan extension and preventive effects of calorie restriction on tumor development: Possible link between central neuroendocrine system and peripheral metabolic adaptation
- Chiba Takuya,Dong Kesu,Nishizono Shoko,Shimokawa Isao
- The Journal of Physical Fitness and Sports Medicine 2(3), 259-266, 2013
- … Recent studies revealed that the molecular mechanisms underlying CR-mediated anti-aging effects may be regulated by a confined number of signal transduction pathways that are triggered by neuropeptide Y (NPY) neurons in the neuroendocrine system. … On the other hand, possible peripheral regulators of the beneficial effects of CR involve a transcriptional regulator complex, the hepatocyte nuclear factor 4α/peroxisome proliferator-activated receptor gamma coactivator 1-α (HNF-4α/PGC-1α) complex. …
- NAID 130003379966
- Neuropeptide Y activates phosphorylation of ERK and STAT3 in stromal vascular cells from brown adipose tissue, but fails to affect thermogenic function of brown adipocytes
- Shimada Kohei,Ohno Yuta,Okamatsu-Ogura Yuko,Suzuki Masahiro,Kamikawa Akihiro,Terao Akira,Kimura Kazuhiro
- Peptides 34(2), 336-342, 2012-04
- … The thermogenic function of brown adipose tissue (BAT) is increased by norepinephrine (NE) released from sympathetic nerve endings, but the roles of NPY released along with NE are poorly elucidated. … Here, we examined effect of NPY on basal and NE-enhanced thermogenesis in isolated brown adipocytes that express Y1 and Y5 receptor mRNA. … Treatment of cells with NPY did not influence the basal and NE-enhanced rates of oxygen consumption and cAMP accumulation. …
- NAID 120004066090
Related Links
- Buy NPY Receptor antibodies from Santa Cruz. Choose from 1 monoclonal and 18 polyclonal NPY Receptor antibodies. NPY Receptor si/shRNA products also available. ... HOVERcruz ,を紹介します。 a unique system for rapid ...
- Agonists Cat.No. Product Name / Activity 2035 BWX 46 Highly selective NPY Y 5 agonist 1177 Neuropeptide Y 13-36 (porcine) NPY Y 2 receptor agonist 1153 Neuropeptide Y (human, rat) Influences feeding and sexual behavior 1173
★リンクテーブル★
[★]
- 関
- NPY receptor
[★]
- 英
- neuropeptide Y receptor、NPY receptor
- 関
- ニューロペプチドYレセプター
[★]
- 英
- neuropeptide Y receptor、NPY receptor
- 関
- ニューロペプチドY受容体
[★]
- 関
- neuropeptide Y
- 同
- neuropeptide Y
[★]